All Stories

  1. Calculation of Myocardial Percentage Collagen, Mast Cell Count and Presence of Arteriosclerosis in Dogs With Myxomatous Mitral Valve Disease and Control Dogs–A Pilot Study
  2. Using a Spectrum of Care Approach to the Diagnosis and Staging of Canine Myxomatous Mitral Valve Disease
  3. Aged Zebrafish as a Spontaneous Model of Cardiac Valvular Disease
  4. Fatal consequences of feline coronavirus infection are associated with virus persistence and a distinct adaptive immune repertoire
  5. Rapid Screening of Anticoagulation Compounds for Biological Target-Associated Adverse Effects Using a Deep-Learning Framework in the Management of Atrial Fibrillation
  6. Sympathetic reactivity to physiological stress is associated with expanded cardiac extracellular volume in humans
  7. Accelerometer-derived classifiers for early detection of degenerative joint disease in cats
  8. Management of preclinical mitral valve disease in dogs
  9. A Deep Learning Methodology for Screening New Natural Therapeutic Candidates for Pharmacological Cardioversion and Anticoagulation in the Treatment and Management of Atrial Fibrillation
  10. Transcriptomics, Proteomics and Bioinformatics in Atrial Fibrillation: A Descriptive Review
  11. Transcriptomics, Proteomics and Bioinformatics in Atrial Fibrillation: A Descriptive Review
  12. Accelerometer-derived classifiers for early detection of degenerative joint disease in cats
  13. Approach to dealing with acute heart failure in cats and dogs
  14. Comparisons of keratinocyte chemoattractant (KC) and monocyte chemoattractant protein-1 (MCP-1) between myxomatous mitral valve disease stages in dogs - a pilot study
  15. Prevalence of gastroesophageal reflux in dogs undergoing MRI for a thoracolumbar vertebral column pathology
  16. Heart rate variability during high‐speed treadmill exercise and recovery in Thoroughbred racehorses presented for poor performance
  17. Improved Ca2+ release synchrony following selective modification of Itof and phase 1 repolarization in normal and failing ventricular myocytes
  18. Validation of a focused echocardiographic training program in first opinion practice
  19. 21st century research—One Health, resilience, welfare, and disease
  20. Training the equine respiratory muscles: Inspiratory muscle strength
  21. The microvascular endothelial glycocalyx: An additional piece of the puzzle in veterinary medicine
  22. Circulating hyaluronan as a marker of endothelial glycocalyx damage in dogs with myxomatous mitral valve disease and dogs in a hypercoagulable state
  23. Training the equine respiratory muscles: Ultrasonographic measurement of muscle size
  24. The prevalence of ultrasonographic gastrointestinal wall changes in dogs with acute pancreatitis - a retrospective study (2012-2020)
  25. Calculation of myocardial percentage collagen and mast cell count in dogs with myxomatous mitral valve disease and control dogs – a pilot study
  26. Three-Dimensional Printed Models of the Heart Represent an Opportunity for Inclusive Learning
  27. Prevalence of ultrasonographic gastrointestinal wall changes in dogs with acute pancreatitis: A retrospective study (2012‐2020)
  28. Effect of preoperative administration of atenolol to dogs with pulmonic stenosis undergoing interventional procedures
  29. Endothelial glycocalyx is damaged in diabetic cardiomyopathy: angiopoietin 1 restores glycocalyx and improves diastolic function in mice
  30. Transvalvular pulmonic stent angioplasty: procedural outcomes and complications in 15 dogs with pulmonic stenosis
  31. Diagnostic Rounds: ECG 101
  32. Computed tomographic staging of dogs with anal sac adenocarcinoma
  33. Clinical findings associated with N‐terminal pro‐B‐type natriuretic peptide measurement in dogs and cats attending first opinion veterinary practices
  34. Inspiratory muscle training for the treatment of dynamic upper airway collapse in racehorses: A preliminary investigation
  35. Evaluation of serum cardiac troponin‐ I concentrations for diagnosis of infective endocarditis in dogs
  36. DETERMINATION OF VERTEBRAL HEART SCALE AND ECHOCARDIOGRAPHIC MEASUREMENTS IN HEALTHY ANESTHETIZED AFRICAN WILD DOGS (LYCAON PICTUS) IN HUMAN CARE
  37. The equine diaphragm: A novel technique for repeatable ultrasound measurement
  38. Focused cardiac ultrasound and point‐of‐care NT‐proBNP assay in the emergency room for differentiation of cardiac and noncardiac causes of respiratory distress in cats
  39. PetSavers
  40. Monitoring congestive heart failure
  41. Long‐term biological variability and the generation of a new reference interval for plasma N‐terminal pro‐B‐type natriuretic peptide in Labrador retrievers
  42. Investigation of focused cardiac ultrasound in the emergency room for differentiation of respiratory and cardiac causes of respiratory distress in dogs
  43. Arrhythmogenic late Ca 2+ sparks in failing heart cells and their control by action potential configuration
  44. Measurements of echocardiographic indices and biomarkers of kidney injury in dogs with chronic kidney disease
  45. What can changes in serial measurements tell us about prognosis in myxomatous mitral valve disease?
  46. Correction: Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
  47. Exploring early life events including diet in cats presenting for gastrointestinal signs in later life
  48. A new hope? Transvascular pulmonic stents in six dogs with severe pulmonic stenosis
  49. Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?
  50. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease
  51. Sample Size Determination for Evaluation of Time Domain Heart Rate Variability Indices in Canine Lameness
  52. Pathology and prognosis of canine myxomatous mitral valve disease
  53. Treatment of dogs with compensated myxomatous mitral valve disease with spironolactone—a pilot study
  54. Anodal stimulation in two dogs with transvenous permanent bipolar pacemakers
  55. Differentiation of Cardiac from Noncardiac Pleural Effusions in Cats using Second‐Generation Quantitative and Point‐of‐Care NT ‐pro BNP Measurements
  56. Clinical Severity Score System in Dogs with Degenerative Mitral Valve Disease
  57. The effects of storage conditions on measurements of canine N-terminal pro-B-type natriuretic peptide
  58. Associations between N-terminal procollagen type III, fibrosis and echocardiographic indices in dogs that died due to myxomatous mitral valve disease
  59. Relationship of Plasma N-terminal Pro-brain Natriuretic Peptide Concentrations to Heart Failure Classification and Cause of Respiratory Distress in Dogs Using a 2nd Generation ELISA Assay
  60. Longitudinal Electrocardiographic Evaluation of Dogs with Degenerative Mitral Valve Disease
  61. Differentiating between feline pleural effusions of cardiac and non-cardiac origin using pleural fluid NT-proBNP concentrations
  62. Relationships between heart rate and age, bodyweight and breed in 10,849 dogs
  63. Relationships between heart rate and age, bodyweight and breed in 10,849 dogs
  64. Associations among serum N-terminal procollagen type III concentration, urinary aldosterone-to-creatinine ratio, and ventricular remodeling in dogs with myxomatous mitral valve disease
  65. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease
  66. Ultrasonographic measurement of flow-mediated vasodilation in dogs with chronic valvular disease
  67. The Combined Prognostic Potential of Serum High-Sensitivity Cardiac Troponin I and N-Terminal pro-B-Type Natriuretic Peptide Concentrations in Dogs with Degenerative Mitral Valve Disease
  68. Gerbode defect associated with blunt trauma in a dog
  69. The effect of protease inhibition on the temporal stability of NT-proBNP in feline plasma at room temperature
  70. Laboratory evaluation of cardiac disease
  71. Investigating the endothelial glycocalyx in health and disease in dogs